Browse by author
Lookup NU author(s): Noel Monks,
Professor Nicola CurtinORCiD,
Professor Herbie Newell
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
ZD2767P, a nitrogen mustard glutamate prodrug, is currently being evaluated in Phase 1 clinical trials of antibody directed enzyme prodrug therapy (ADEPT). There was no significant relationship between basal glutathione (GSH) concentration and sensitivity to ZD2767P + carboxpeptidase G2 (CPG2) in colorectal tumour cell-lines. Depletion of intracellular GSH using buthionine sulfoximine (BSO) resulted in only a modest potentiation of ZD2767P + CPG2 activity and hence BSO is unlikely to markedly enhance the activity of this ADEPT treatment. (C) 2000 Cancer Research Campaign.
Author(s): Monks, N., Calvete, J., Curtin, N.J., Blakey, D., East, S., Newell, D.R.
Publication type: Article
Publication status: Published
Journal: British Journal of Cancer
Print publication date: 01/01/2000
ISSN (print): 0007-0920
ISSN (electronic): 1532-1827
PubMed id: 10901381
Altmetrics provided by Altmetric